07:00 , Jul 20, 2015 |  BC Week In Review  |  Company News

biOasis, National Research Council Canada, Universite de Sherbrooke deal

biOasis partnered with the National Research Council of Canada and the Universite de Sherbrooke to identify blood-brain barrier (BBB) carrier molecules for use with neurotherapeutics. The partners have been awarded C$2.6 million ($2 million) in...
08:00 , Dec 4, 2014 |  BC Innovations  |  Strategy

Merck Encycles through Canada

The first disclosed grant under Merck & Co. Inc. 's Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin α4b7 inhibitors for inflammatory bowel disease....
07:00 , Aug 4, 2014 |  BioCentury  |  Emerging Company Profile

Encycle: Oral macrocycles

Macrocycle therapies can block protein-protein interactions that are undruggable with small molecules; however, oral availability and cell penetration remain key challenges. Encycle Therapeutics Inc. 's chemistry platform generates drug-like macrocycles against validated targets to treat...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Sanofi, Quebec Consortium for Drug Discovery (CQDM) pharmaceuticals news

Sanofi (Euronext:SAN; NYSE:SNY), Paris, France   Quebec Consortium for Drug Discovery (CQDM) , Montreal, Quebec   Business: Pharmaceuticals   Sanofi's Sanofi Canada unit joined CQDM and said it will contribute up to C$500,000 ($457,750) over...
07:00 , Jun 12, 2014 |  BC Innovations  |  Strategy

CQDM: Canada on the brain

The Quebec Consortium for Drug Discovery and Brain Canada have announced at least C$10 million (US$9.2 million) in funding for a new program to develop tools to accelerate the discovery of neurological disease therapies. Under...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Domain Therapeutics, McGill University, University of Montreal deal

On Dec. 18, 2013, Domain said it partnered with McGill University and University of Montreal (UdeM) to develop biosensors using GPCR technology developed at UdeM. The technology was developed by UdeM under a grant from...
07:00 , Sep 17, 2012 |  BioCentury  |  Product Development

Excited about cycling

New synthesis and screening technologies and the allure of access to previously undruggable targets are driving an explosion of new company formation and deal-making around macrocycles and constrained peptides. While it remains to be seen...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Company News

MaRS Innovation, Quebec Consortium for Drug Discovery (CQDM) chemistry news

MaRS Innovation spun out Encycle Therapeutics Inc. to develop a chemistry technology that cyclizes linear peptides for use in drug discovery research. MaRS said that the technology will increase efficiency of the early-stage discovery process...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

MaRS Innovation, Ontario Brain Institute, Ontario Centres of Excellence, Quebec Consortium for Drug Discovery other news

CQDM partnered with the three Ontario organizations to launch the Quebec/Ontario CQDM Funding Program, which is focused on developing tools for biopharma research. Academic institutions and small to medium-sized enterprises in Quebec and Ontario are...
07:00 , Jun 21, 2012 |  BC Innovations  |  Strategy

GSK completes its Canadian tripod

GlaxoSmithKline plc and the not-for-profit Centre for Drug Research and Development have partnered to fund research from academic institutions across Canada. The deal completes a trio of alliances established by the pharma in the last...